| INTRODUCTION

Ambulatory ECG (AECG)
1 telemetry is typically used to evaluate symptoms such as syncope, dizziness, chest pain, palpitations, or shortness of breath, which may correlate with intermittent cardiac arrhythmias.
Additionally, AECG is used to evaluate patient response to initiation, revision, or discontinuation of arrhythmic drug therapy and to assess prognosis in specific clinical contexts. The purposes of this statement were (1) to review how contemporary AECG devices acquire and process ECG signals and how they should be interpreted; (2) to review appropriate utilization of these devices in the management of cardiovascular disease; and (3) to promote standards that will improve the accuracy and appropriate use of the AECG in clinical practice.
The writing group recognizes that technical details of the processing and recording of AECGs may be unfamiliar to some clinicians.
Accordingly, a major purpose of this document was to provide clinicians with insight concerning current technology and its implications for clinical interpretation. Moreover, evolving technologies permit integration of cardiac data with other monitored variables, extending traditional applications.
This document builds upon previous published professional society guidelines from 1999 to 2009 Crawford et al., 1999; Drew et al., 2004; Kadish et al., 2001) , and focuses most intently on the evolution and advancement of AECG technology and its impact on clinical decision making and practice.
| METHODOLOGY OF DOCUMENT PREPARATION
The writing committee consisted of experts in the field representing 
| SECTION 1: MODALITIES, TECHNOLOGY, AND EQUIPMENT
| Ambulatory ECG monitoring techniques and systems
External AECG serves to detect, document, and characterize abnormal cardiac activity during ordinary daily activities, extending the role of ECG recording beyond the bedside 10-s standard 12-lead resting ECG (Crawford et al., 1999; Kadish et al., 2001 ). AECG technology is noninvasive, easy to use, relatively inexpensive, and readily available.
Pioneering work by Norman "Jeff" Holter led to the first prototype of "mobile" cardiac telemetry device, requiring 85 pounds of equipment, worn on his back while riding a stationary bicycle and used a radio-ECG (circa 1947) (Del Mar, 2005; Kennedy, 2006) . Modern AECG devices are light and inconspicuous, and through continuous beat-to-beat ECG monitoring, automatic arrhythmia detection and wireless transmission of data in near real time improve diagnostic yield and provide enormous improvements in efficiency and ease of use (Charitos et al., 2012; Hanke et al., 2009; Locati et al., 2016; Mittal, Movsowitz, & Steinberg, 2011; Reiffel, Schwarzberg, & Murry, 2005; Rosenberg, Samuel, Thosani, & Zimetbaum, 2013; Rothman et al., 2007; Vasamreddy et al., 2006) .
Miniaturization of instrumentation is progressing rapidly in con-
cert with evolution of microelectronic circuits (Soundarapandian & Berarducci, 2009 ) accompanied by evolution of wireless networking technologies and in particular the emergence of secure Smart Bluetooth (ver. 4.2) optimized for medical applications. Some AECG devices also feature multiple biological signal sensors that allow for simultaneous recording of multilead ECGs along with respiratory rate, peripheral oxygen saturation, physical activity, skin temperature, arterial pulse pressure, and other parameters, to provide the comprehensive evaluation of patients with complex disorders, such as heart failure or sleep apnea syndromes (Locati, 2002) . These sensors extend AECG functions from simply ECG to include ambulatory vital signal monitoring.
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Challenges persist for both manufacturers and clinicians to provide reliability and functionality, yet handle transmissions and analyze and store large amounts of data securely. In asymptomatic patients and situations when abnormalities occur infrequently, AECG devices capable of very long recording periods of up to several weeks and even months can be used. Poor tolerability of wireelectrode systems (especially when recording is prolonged) and adverse skin reactions challenge patient compliance. Table 1 and 
| Continuous single and multilead external recorders wire-lead transmission (Holter monitors)
Ambulatory ECG recorders are typically small, lightweight devices (200-300 gm) that use soft wire patient cables and standard wet gel Frequency of symptoms should dictate the type of recording: longer term ECG monitoring is required for more infrequent events. Correlation (or lack of) of symptoms and arrhythmias is key. The most appropriate clinical workflow may include a continuous (short-term 24 hr and up to 7 days) AECG monitoring, which if unsuccessful, is followed by intermittent external loop recording (long-term from weeks to months). For those patients remaining undiagnosed after prolonged noninvasive monitoring, implantable loop recorders (ILR) may be necessary. electrodes worn continuously to record ECG data. Recordings may be in 2-channel (two independent bipolar leads), 3-channel, 12-channel, or EASI lead formats. Although traditionally used for 24-48 hr, some newer generation devices permit recording periods up to 30 consecutive days.
Traditional AECG recorders require active patient participation.
Patients may manually record in a diary or mark the occurrence of symptoms by pressing a built-in switch on the recorder. AECG data are analyzed postrecording on a dedicated workstation.
| Continuous single-or two-lead external recorders with wireless transmission (patch ECG monitors)
Wearable adhesive "patch ECG monitors" constructed with embedded electrodes, with wireless data transmission, are a new class of AECG recording devices (Lobodzinski, 2013; Lobodzinski & Laks, 2012) .
These on-skin wearable devices, which remove the need for patient cable wires and discrete electrodes, can record 1-or 2-lead electrogram from two closely spaced electrodes worn continuously for up to 14 days. A compact, lightweight patch affixed over the patient's left pectoral region is comfortable to wear and does not interfere with patients' daily routines as it is water resistant and can remain on the patient during showering and exercise. Patients can press a button to mark symptomatic episodes. Proprietary algorithms diagnose cardiac rhythms based on beat-by-beat QRS detection. Up to 7-14 days of ambulatory monitoring yields a high rate of arrhythmia identification (Rosenberg et al., 2013; Turakhia et al., 2013) . Newer patch ECG monitors are also capable of recording body temperature, patient activity, respiration, and galvanic skin reflex (Ajami & Teimouri, 2015) .
Adhesive ECG patch devices with embedded electrodes and sensor shirts featuring textile electrodes (sometimes called "textrodes") are better accepted by the patients and improve compliance with extended monitoring (Lobodzinski, 2013; Lobodzinski & Laks, 2008 Perez de Isla et al., 2011) .
| Intermittent external patient-or eventactivated recorders (external loop recorders)
Intermittent autotriggered loop recorders are typically single bipolar lead devices. Loop recording is generally performed over longer periods, ranging from weeks to months. Continuous memory-loop recorders are often equipped with an autotrigger function that captures the "prior-to-event to postevent" portion of the ECG signal into the device memory. Intermittent loop recorders can be either external devices ("external loop recorder" or ELR) or implantable devices ("implantable loop recorder" or ILR) . Both ELR and ILR record ECG tracings lasting from few seconds to several minutes (in some cases up to 1 hr, to include the onset and offset of arrhythmias) and can detect both symptomatic and asymptomatic arrhythmias (by means of autotrigger functions). ELR and ILR detect, record, and store the occurrence of infrequent specific rhythm disorders (such as pauses, bradycardia, supraventricular, and ventricular arrhythmias).
ELRs need to be worn continuously by the patient and are attached to the chest by a variety of carrier systems that include wire electrodes.
Upon event detection, ECG data are stored for a predefined amount of time prior to the event (looping memory) and a period of time after the activation. As documented by SYNARR-Flash study, prolonged 4-week ELR monitoring has a high yield for evaluation of syncope and palpitations (Locati et al., 2016) .
| Intermittent external patient-or automatically activated postevent recorders (external event recorders)
Simpler nonlooping postevent recorders are not worn continuously.
Rather, these portable devices with built-in electrodes are applied directly on the chest (or held by both hands) to record a very brief duration single-lead ECG signal during symptoms. Recently, new smartphone-based ECG recording systems have been developed (Haberman et al., 2015) . These record a single-lead electrogram from closely spaced stainless steel electrodes embedded into the smartphone-holding case (also see Section 9). Patient-activated postevent recorders have the potential to transmit the "near-real-time" event ECG data, provided patients recognize symptoms and activate the recording in a timely fashion. The event data are transmitted usually via digital cell phone networks directly to the data monitoring center for immediate analysis. Notification alarms are also generated and sent directly to the caregivers.
| External real-time cardiac telemonitoring systems-mobile cardiac telemetry
Mobile cardiac telemetry (MCT) devices combine the benefits of AECG recorders, ELRs, and nonlooping event recorders. Often, these are single-lead electrogram recording devices embedded either in a patch, necklace pendant, or a chest belt carrier, as well as conventional ECG electrodes. Worn continuously, these devices are capable of real-time streaming, transmitting a loop, or a single-event electrogram directly to the reading center via a wireless link. Newest iterations can connect to any WiFi access point to transfer data.
The MCT data are processed in a reading center on the back end of the monitoring system. The arrhythmic events are analyzed by trained technicians, and alarms are distributed to the caregivers. MCT devices are also equipped with real-time signal processing algorithms providing detection of cardiac arrhythmias. Some MCTs use a multilead standard 3-channel Holter-like recording wire-electrode systems (Rothman et al., 2007; Tsang & Mohan, 2013) .
| Selection of appropriate technologies
The selection of appropriate technology has to take into account diagnostic power, monitoring, and risk stratification accuracy with consideration about cost-effectiveness, patient acceptance, degree of automaticity, and local availability and experience, as well as, symptom frequency, the overall patient clinical condition, and the probability of life-threatening arrhythmia (Tables 1 and 2 ). MCT provides the benefit of real-time, comprehensive data without requiring the patient to participate in the process of data transmission.
Unlike AECG recorders, these devices allow immediate transmission of information; compared with looping event recorders, they gather more information and allow remote data transfer while overcoming Major advantages and limitations of AECG techniques are summarized in Table 3 .
| AECG signal acquisition, processing, and interpretation
There have been major advances in recording and signal processing techniques resulting in enhanced recording fidelity and more sophisticated analysis software (Kennedy, 2006) .
| Electrodes for AECG applications
Virtually, all wire and embedded electrodes used by AECG monitoring devices utilize wet gel electrodes. These are nonpolarizable electrode types, with a silver-silver chloride (AgCl) element coated with an ionically active gel. Polarizable silver textrodes (textile electrodes) embedded in the shirt/vest carrier are also now available (Lobodzinski & Laks, 2008; Perez de Isla et al., 2011 (Keller & Lemberg, 2007; Knight et al., 1999 Knight et al., , 2001 Krasnow & Bloomfield, 1976; Márquez, Colín, Guevara, Iturralde, & Hermosillo, 2002) .
Selection of optimal monitoring electrodes for AECG applications is of critical importance to signal fidelity (Ackermans et al., 2012; Lobodzinski & Laks, 2012; Locati, 2002; Zimetbaum & Goldman, 2010; Zimetbaum, Kim, Josephson, Goldberger, & Cohen, 1998) . Optimal electrode application includes the following: (1) shaving the skin if necessary; (2) removing dead skin cells by rubbing the area with a rough paper or cloth; (3) using electrodes from air tight packages; and (4) paying attention to expiration dates on the electrodes packages (Kligfield et al., 2007) .
| Holter lead configurations
Ideally, all AECG devices should use 12-lead configuration. Due to technological, patient acceptance, and economic reasons, however, only few AECG monitors have 12-lead system capabilities. A 12-lead
Holter lead system shown in Figure 2a EASI reduced leads system. EASI is a reduced lead system suitable for continuous ECG monitoring. It is an alternative to both the commonly used 5-electrode monitoring system and the traditional 10-electrode Mason-Likar 12-lead ECG system. The EASI lead configuration enables continuous reconstructed 12-lead ECG ambulatory monitoring using only five electrodes. The EASI 12-lead ECG is derived from a set of four recording electrodes and one reference electrode. The placement of these leads is as follows: E: lower extreme of the sternum, A: left mid-axillary line, same transverse line as E, S: sternal manubrium, I: right mid-axillary line, same transverse line as E, R: fifth electrode is the body potential reference and can be placed anywhere on the torso monitoring position place the arm electrodes over the outer clavicles and the right leg electrode (body potential reference) at the sternum.
The precordial electrodes are placed in the standard positions (Drew & Finlay, 2008; Welinder, Wagner, Maynard, & Pahlm, 2010) . When 12-lead AECG monitors are not available, a "pseudo-standard" lead system may be used. These are usually either 2-channel/7-electrode frontal plane configurations.
The EASI lead system (Figure 2b ) is a reduced 5-electrode system that uses the E, A, and I electrodes from the Frank lead system and adds an "S" electrode at the top of the mid sternum, along with a body reference electrode to provide orthogonally oriented signals. This eliminates the need to determine intercostal spaces and avoids the breast. EASI lead system makes use of the transformation coefficient matrix that produce synthesized 12-lead ECGs. EASI is well suited for AECG applications because of the absence of limb electrodes, which usually produce signal artifacts in active subjects.
Most patch ECG monitors, ELR, event recorders, and MCT monitors available today feature only a single lead derived from two closely spaced embedded or wired electrodes (Lobodzinski, 2013; Lobodzinski & Laks, 2012) . A variety of single-lead configurations are only possible in wire-electrode systems, the most common being a chest-modified V 5 (CM5), a chest-modified V 3 (CM3), and a modified inferior lead.
Specific lead configurations can be chosen in specific situations (e.g., in case of a patient undergoing AECG monitoring for ischemia, the AECG lead configuration should be chosen to mimic those leads with the greatest ST-segment change during exercise).
Ambulatory ECGs recorded with torso placement of the extremity electrodes cannot be considered equivalent to standard ECGs for all purposes and should not be used interchangeably with standard ECGs for serial comparison (Papouchado, Walker, James, & Clarke, 1987) .
For example, a 12-lead ECG is the diagnostic test of choice for long QT syndrome (LQTS), rather than an AECG.
| AECG processing
All modern AECG instrumentation today is digital and subject to regulatory guidelines (Guidance for Industry and Food and Drug Administration Staff, 2003) . The front end is typically a highly integrated system on the chip (SoC) responsible for surge protection (defibrillator shock), analog-to-digital conversion, digital filtering, and calibration. The processing flow of the AECG signal starts with the biopotential signal acquisition front-end subsystem of the monitor.
Common-mode rejection ratio, or CMRR, is one of the most important performance parameters for ECG system applications and is subject to regulatory approval. A driven right leg circuit or "DRL" circuit is an electric circuit that is added to ECG signal amplifiers to reduce common-mode interference. SoC provide multichannel, simultaneous sampling, 24-bit, delta-sigma (ΔΣ) analog-to-digital converters (ADCs) with built-in programmable gain amplifiers capable of resolving signals as small as pico volts. Unfortunately, the patient's body can also act as an antenna which picks up electromagnetic interference, especially 50/60 Hz noise from electrical power lines. This interference signal induces voltages much greater than the ECG signal itself, thus making it very challenging to measure. right leg driver circuitry is used to eliminate interference noise by actively canceling the interference signal (Winter & Webster, 1983) .
The AECG digital signal must then be amplified and low-pass filtered in SoC to prevent aliasing errors. Next, the digital AECG is bandpass and notch filtered to eliminate or suppress low-frequency noise caused by baseline wander, respiration, and higher frequency noise cased by muscle tremors and induced electromagnetic interference.
Once amplified, filtered, and smoothed, the analysis of the AECG can proceed. The end result of this operation is the delineation of the AECG into P, QRS, and T waveforms. Global waveform measurements, such as duration, amplitudes, ratios, are derived from individual lead data or from mathematical combinations of simultaneously acquired individual lead data and stored in the measurement matrix. The accuracy of the waveform classification highly depends on the redundancy of the information contained in a multilead system. Generally speaking, the higher the number of the leads the higher the complex detection precision.
| Mobile cardiac telemetry ECG data transmission
The MCT devices use either packet-oriented mobile data service on the 2G and 3G cellular communication system (GPRS) or a combination of Bluetooth with a Wi-Fi 802.11 b/g/n relay station (Engel et al., 2011) . GPRS uses powerful algorithms and encryption techniques on security controls that include subscriber identity confidentiality, subscriber identity authentication, user data confidentiality on physical connections, connectionless user data confidentiality, and signaling information element. The MCTs that use Bluetooth security feature transmit data via relay (smartphone, tablet, and dedicated transmission device) to the remote reading centers. The newly announced Smart Bluetooth low-energy protocol used by the latest MCT devices also features robust security measures. The weakest link in relay type of AECG data transmission is the HTTPS data transmission protocol widely used over the Internet. shifts, heart rate variability (HRV), QT dynamics and T-wave variability, T-wave alternans (TWA), heart rate turbulence (HRT) (Hoefman, Weert, Reitsma, Koster, & Bindels, 2005; Joshi, et al., 2005; Salleh et al., 2017 (Figure 3a) , or pseudo-ventricular tachyarrhythmia (Figure 3b,c) .
| AECG analysis and interpretation
A second group of artifacts is probably related to intermittent impairment of electrode contact or recorder problems in older recording systems that can result in tape slowing or intermittent stoppage (Krasnow & Bloomfield, 1976; Márquez et al., 2002) . These artifacts result in pseudo-pauses that can simulate sinus arrest, pacemaker malfunction, or high-degree atrioventricular conduction block. The majority of artifacts can be recognized from simultaneous multichannel ECG.
In contrast to the role of the more common AECG artifacts, fail- (Krasnow & Bloomfield, 1976) . Errors of omission include failure to properly address patients with potentially serious arrhythmic events.
| SECTION 2: CLINICAL INDICATIONS-DIAGNOSTICS
| Syncope
Syncope (loss of consciousness from either sudden or gradual but persistent decrease of blood flow to the brain as a consequence of low cardiac output) may be due to primary electrical problems (bradycardia/tachycardia) or hemodynamic causes. The role of the AECG is to identify Symptom/rhythm correlation remains the cornerstone of the diagnostic efforts in syncope to confirm the involvement of the cardiac electrical system in the origin of syncope (Morillo & Baranchuk, 2004 (2015) nature (Baron-Esquivias et al., 2010) . (Morillo & Baranchuk, 2004) .
The type of recorder and the duration of recording should be tailored to the individual patient's history, but in general, the diagnostic yield is limited and dependent on the frequency of clinical symptoms.
Extended recordings may improve diagnostic yield. In 1 trial, the overall probability of obtaining a symptom-rhythm correlation increased from 22% to 56% for 48-hr Holters compared to 1 month of ECG loop recording (Sivakumaran et al., 2003) . In another study, the median time for recording a symptom-rhythm correlation was 16 days for patients assigned a loop recorder as their first diagnostic strategy and symptom-rhythm correlation was obtained in 87% of patients by 1 month of monitoring (Bass et al., 1990) . Much longer monitoring using ILRs can further improve the diagnostic yield for syncope, as high as 85% in some studies (Cotter et al., 2013) .
Although exercise-induced arrhythmias are typically worked up via an exercise treadmill examination, there may be value in using AECG recording, especially for adolescents. This may facilitate recordings during more natural activities and also stimulate levels of exertion not achieved in an artificial environment, enhancing symptom-rhythm correlation.
| Palpitations
Palpitations are the most frequent indication for AECG, and one of the main reasons why AECG was originally developed. Up to 20% of outpatients present with palpitations and most of the cases have benign causes (Kroenke, Arrington, & Mangelsdorff, 1990) . Although a detailed history, physical examination, and 12-lead ECG are sufficient to make a definitive diagnosis in up to one-third of patients with palpitations, in the remainder AECG is the most cost-effective clinical tool (Weber & Kapoor, 1996) .
Ambulatory ECG monitoring for symptom-ECG correlation is indicated for the following groups of patients with unexplained palpitations: (1) when history, physical examination, and 12-lead ECG suggest a possibility of arrhythmia; (2) in the setting of diagnosed structural heart disease, family history of sudden cardiac death (SCD), or inherited channelopathy with known risk of arrhythmia; (3) when patients need reassurance and specific explanation of their symptoms, and (4) when symptoms warrant therapy and specifics of treatment are dependent on a formal arrhythmic diagnosis (e.g., ablation, antiarrhythmic therapy).
Ambulatory ECG monitoring is the key tool for the diagnosis of unexplained, well-tolerated recurrent palpitations. Clinical presentation and frequency of palpitations should be taken into consideration when selecting the device (Crawford et al., 1999; Mittal, 2015; Raviele et al., 2011 to be more cost-effective (Fogel, Evans, & Prystowsky, 1997) . It has been shown that 2 weeks of ECG monitoring provide the best balance between diagnostic yield and associated cost (Zimetbaum et al., 1998) . The diagnostic yield of AECG directly correlates with the duration of AECG monitoring and depends on the percentage of "accurate reporters" in the studied population. Typically, diagnosed rhythms reflect prevalence of arrhythmias in the studied populations (Table 2 ).
| Chest pain and coronary ischemia
Ambulatory ECG monitoring can be utilized to diagnose the etiology of chest pain (both atherosclerotic coronary artery disease and Prinzmetal's variant angina), identify episodes of atypical chest pain that do not have an apparent manifestation on the surface ECG, and assess the magnitude of "ischemic burden," the product of duration of ischemia and the magnitude of ST-segment depression. The majority of episodes of ambulatory ischemia in patients with coronary disease are asymptomatic, and therefore objective ECG monitoring, such as with the AECG, can be used to identify the severity of ischemia during daily activities .
For a diagnosis of ischemia, ST-segment depression of at least 0.5-1.0 mV (0.5-1.0 mm) lasting for at least 1 min before returning to normal should be seen (Conti, Bavry, & Petersen, 2012) . Reported rates of ST-depression sensitivity (62%) and specificity (61%) as detected by continuous ECG in patients with angiographically defined chest pain and known coronary artery disease are similar to those derived from an exercise treadmill test (67% and 65%, respectively) using similar lead positions. With AECG monitoring, nearly one-half of patients with stable coronary artery disease exhibit transient ST-segment depressions that likely represent ischemic events (Pepine, Geller, & Knatterud, 1994; Smith, Amsterdam, & Balady, 2000) . This has important prognostic information, potentially beyond the findings obtained during an exercise treadmill test. In one study, after multivariable adjustment, only ST-segment depression during AECG monitoring,
and not ST-segment depression during exercise testing, significantly predicted worse outcomes (Rocco et al., 1988) . In patients with unstable coronary syndromes, silent ischemia can predict both short-term and long-term risk (Gibson et al., 2009; Gottlieb, Weisfeldt, Ouyang, Mellits, & Gerstenblith, 1987; Langer, Singh, Freeman, Tibshirani, & Armstrong, 1995; Patel et al., 1997; Scirica et al., 2009 ).
Ambulatory ECG monitoring has also been utilized to diagnose and manage patients with the rare syndrome of Prinzmetal's variant angina, but confirmation of adequate therapeutic prevention of vasospasm episodes has been primarily based on provocative testing in the cardiac catheterization laboratory (Bayés de Luna et al., 2014; Waters, Szlachcic, Theroux, Dauwe, & Mizgala, 1981) .
In patients suffering ST elevation myocardial infarction (STEMI), early reperfusion via percutaneous coronary intervention (PCI)
remains the critical therapeutic intervention. As PCI resources are only available in specific institutions, prehospital diagnosis has specific practical advantages: directing emergency transport to the optimal facility, bypassing the emergency department, and preparation at the receiving facility for emergent PCI and associated treatment.
The emergency transport system must be capable of recording a 12-lead ECG and transmitting the ECG to a center that can provide skilled confident interpretation. The Danish health system has formally implemented such a system for several years, processing about 4,000 ECGs per year, and observed that 81% of prehospital diagnoses of STEMI underwent emergent PCI resulting in an acceptable low "false-positive" rate (Clemmensen et al., 2013) . This rapid triage system has been associated with a decline in 30-day mortality rates, confirming technical feasibility and suggesting measurable clinical impact.
| Special considerations for pediatric patients
AECG in pediatric patients bears special consideration. Indications are similar to adult patients, largely predicated upon symptom frequency and duration, and also for risk stratification and assessing treatment efficacy.
Palpitations are a common presenting symptom. Arrhythmia correlation during AEGM was noted in 10%-15% of pediatric patients experiencing palpitations. Conversely, sinus tachycardia is identified in nearly 50% of patients with the same symptoms (Dick, McFadden, Crowley, & Rosenthal, 1979; Fyfe, Holmes, Neubauer, & Feldt, 1984; Goldstein, Hesslein, & Dunnigan, 1990; Karpawich, Cavitt, & Sugalski, 1993) . In one single-center experience of 495 pediatric patients, transtelephonic electrocardiographic event monitors (TTMs) yielded a useful diagnosis in 48% (Saarel et al., 2004) . Conversely, >50% patients in this study failed to transmit a single, legible ECG while symptomatic, highlighting the limitation of patient-activated equipment in the pediatric population. This is compounded by age-related compliance: Most young children (<5 years) are unable to comply with event triggered monitoring. Clinicians have circumvented this issue by allowing parents, caregivers, or even teachers to provide the activation. Of course, in time-sensitive events, this is not always plausible which remains a major limitation of this equipment.
The evaluation of syncope creates a diagnostic challenge with patient-activated AECG. Temporary loss of consciousness precludes patient triggered activation. As such, clinicians recommend outpatient cardiac telemetry with continuous recording independent of patient activation. In some circumstances, ILRs may ensure capture of syncopal events. A cardiac cause of chest pain is extremely unlikely in the pediatric population. In a large prospective study, <5% of patients were identified as having a cardiac cause of their chest pain (Selbst, Ruddy, Clark, Henretig, & Santulli, 1988) . Therefore, AECG has low diagnostic yield but has utility to exclude cardiac-or rhythm-related etiologies to symptoms as a means of providing reassurance to patients and families.
AECG can be useful for risk assessment. In asymptomatic patients heart disease (CHD). For example, AECG is a class I recommendation for patients with repaired CHDs or for patients with significant residual, hemodynamic abnormalities (Crawford et al., 1999) . In adult patients with CHDs, AECG is considered as a class IIa for monitoring of arrhythmias and/or conduction disturbances (Baumgartner et al., 2010; Khairy et al., 2014) . The finding of nonsustained ventricular tachycardia is considered a significant risk factor for sudden death in patients with hypertrophic cardiomyopathy (HCM) (Elliott et al., 2014; Gersh et al., 2011) . Indications for pacemaker implantations in patients with congenital complete heart block are largely predicated on the presence of prolonged pauses, low average heart rates, or complex ventricular ectopy on Holter monitoring (Epstein et al., 2013) .
Despite important limitations in the pediatric patient, AECG has become a standard diagnostic tool for rhythm assessment. As technology improves and devices become more compatible and less cumbersome for our "smaller" population (e.g., patch technologies with continuous monitoring), the utilization of these devices and their diagnostic power will undoubtedly increase.
| SECTION 3: CLINICAL INDICATIONS-PROGNOSIS AND RISK STRATIFICATION
Ambulatory ECG detection of transient arrhythmias, electrical pertubations, or autonomic disturbances has been used for risk stratification although its value varies according to clinical context. In the absence of structural and/or electrical heart disease, the prognostic value of these recordings is generally weak or absent.
| Ischemic heart disease and postinfarction patients
Premature ventricular complexes (PVCs) and nonsustained ( NSVT in more than half of the patients in the overall cohort. Moreover, both short and longer NSVT episodes (4-7 or ≥8 beats) were significantly associated with 2.3-to 2.8-fold increased annual SCD risk, especially when associated with the presence of myocardial ischemia irrespective of the presence of prior myocardial infarction (Scirica et al., 2010) . While short-lasting NSVT episodes occurring within the first 48 hr after admission did not carry the same risk, similar episodes that occurred beyond 48 hr were associated with significant (2.9-to 3.7-fold) annual SCD risk. The failure to link an effective therapeutic intervention following these AECG findings has probably limited its utilization in clinical practice.
In the late (>24 hr) postacute MI inpatient period, the detection of NSVT episodes has been associated with a higher rate of sustained VT and with subsequent increased mortality (Cheema, Sheu, Parker, Kadish, & Goldberger, 1998; Pires et al., 2001) . Following discharge,
NSVT has limited prognostic significance in post-MI patients. NSVT detection among MI survivors yielded low prognostic value for subsequent mortality and no prognostic value when only arrhythmic events were considered (Hohnloser et al., 1999) . Although the presence of NSVT in 24-hr ECG recording was an independent predictor of adverse prognosis in the Autonomic Tone and Reflexes After
Myocardial Infarction trial and raised interest in Holter monitoring for risk stratification (La Rovere et al., 2001 ), in the current era in which post-MI patients are adequately reperfused and treated with betablockers, NSVT may not serve as an independent predictor of longterm mortality especially when other covariates such as LVEF are taken into account (Bloch et al., 2010; Hofsten, Wachtell, Lund, Molgaard, & Egstrup, 2007; Katritsis, Siontis, & Camm, 2013) . Therefore, AECG is currently not commonly used.
After hospital discharge following MI, left ventricular scarring and remodeling may yield a suitable electrophysiological substrate for the genesis of both nonsustained and sustained ventricular arrhythmias.
Although post-MI studies published in the early 1980s and 1990s
identified frequent PVCs and NSVT as strong independent predictors of arrhythmia risk and SCD in MI survivors with left ventricular dysfunction (Doval et al., 1996) , in the modern era, the independent predictive value of NSVT is not established (Buxton et al., 2007; Katritsis et al., 2013; Maggioni et al., 1993; Makikallio et al., 2005; Singh, Fisher, Carson, & Fletcher, 1998; Teerlink et al., 2000) . This discrepancy could be explained by the extreme temporal variability of NSVT in different patient populations in association with the wide range in the timing of Holter recordings.
On the other hand, NSVT was shown to be a significant predictor of SCD in post-MI patients with a relatively preserved ejection fraction (LVEF > 35%), independently of diabetes mellitus, age, and LVEF (Makikallio et al., 2005) . NSVT accompanied by inducibility of sustained VT during programmed ventricular stimulation was associated with an increased risk of SCD (Buxton et al., 1999; Moss et al., 1996) .
Following the Multicenter Unsustained Tachycardia Trial (MUSTT) (Buxton et al., 1999) , there is a role for AECG for NSVT detection in post-MI patients with LVEF 35%-40% as electrophysiologically guided ICD implantation improves survival (Epstein et al., 2013; Priori et al., 2015) .
In conclusion, in patients with prior MI treated with reperfusion and beta-blockers, NSVT is not an independent predictor of long-term mortality when other covariates such as LVEF are taken into account.
Across studies of ischemic heart failure patients, the predictive value of irregular ventricular activity in ambulatory Holter recordings remains debatable. However, prolonged (>8 beats) and rapid (>120 beats per minute) episodes of NSVT may justify further exploration of the SCD risk by use of noninvasive or even invasive measures. The detection of any NSVT in patients with borderline EF (e.g., 35%-40%) might prompt further risk stratification and determination of need for ICD using EPS.
| Nonischemic dilated cardiomyopathy
Nonischemic dilated cardiomyopathy (NIDCM) may be the consequence of a variety of causes, including virus-mediated and autoimmune disease, as well as toxic and metabolic, inherited, and tachycardia-induced conditions. Tachycardiomyopathy may result from atrial arrhythmias with rapid and/or irregular ventricular response or frequent ventricular ectopy. In such cases, AECG monitoring is useful to evaluate heart rate or frequency and complexity of ectopy in order to establish diagnosis and/or indications for invasive therapeutic treatment as ablation (Baman et al., 2010; Pedersen et al., 2014) .
Patients with NIDCM die mostly from SCD or heart failure progression (Okutucu & Oto, 2010) . Theoretically, AECG monitoring may be considered as a tool in risk stratification of SCD by detection of NSVT episodes and evaluation of other Holter-based risk markers.
However, in contradistinction to what is reported in patients with ischemic cardiomyopathy, the prognostic value of AECG in NIDCM is rather low and remains controversial (Goldberger et al., 2007 Pedersen et al., 2014) .
The incidence of NSVT in patients with NIDCM varied from 33% to 79% (Doval et al., 1996; Katritsis et al., 2013; Okutucu & Oto, 2010) . Iacoviello et al. (2007) found that NSVT was associated with threefold higher risk of arrhythmic events during follow-up and that prognostic value of NSVT was enhanced by a combination with low LVEF and abnormal QT dynamics. In Marburg Cardiomyopathy study (Grimm, Christ, Bach, Müller, & Maisch, 2003) , NSVT evaluated alone was not associated with an increased risk of arrhythmic events; however, when combined with low LVEF, the risk was eightfold higher. A meta-analysis by de Sousa et al. (2008) showed that the presence of NSVT was a statistically significant predictor, independent of LVEF, of SCD in patients with NIDCM and depressed LVEF. A more recent meta-analysis by
Goldberger et al. (2014) based on 45 studies encompassing over 6,000 patients concluded that NSVT evaluated alone was a significant risk predictor (OR = 2.92, p < .001) of an arrhythmic endpoint defined as sudden or arrhythmic death, cardiac arrest, documented ICD therapy, and documented VT/VF. The negative predictive value of NSVT was as high as 90%; however, its positive predictive value was only 20%.
This study summarized the prognostic role of multiple risk stratifiers and found that the best predictors of unfavorable outcome were TWA, left ventricular end diastolic diameter, EPS, signal averaged ECG, LVEF, QRS duration, and NSVT. None of the markers of autonomic dysfunction such as baroreflex sensitivity, HRV, and HRT was found to be statistically significant. Overall, the data regarding NSVT are weak and do not support routine use of noninvasive techniques in this population.
| Hypertrophic cardiomyopathy
An unfavorable clinical course in HCM is related to an increased risk of SCD, progressive heart failure, and complications attributable to AF. HCM is the most common cause of SCD in young people, notably athletes (Maron et al., 2014) .
Syncope and palpitations are among the most commonly reported complaints in patients with HCM (Elliott et al., 2014; Finocchiaro et al., 2012; Gersh et al., 2011; Monserrat et al., 2003) . Syncopal episodes may be caused by conduction disturbances, paroxysmal atrial arrhythmias with rapid ventricular rate, LV outflow tract obstruction or neurally mediated events, and most ominously, potentially lethal ventricular arrhythmias. Up to 30% of HCM patients present with NSVT episodes on Holter monitoring (Adabag et al., 2005; Monserrat et al., 2003) . The frequency is related to the degree of myocardial fibrosis (Adabag et al., 2008 (Elliott et al., 2014; Gersh et al., 2011) .
Paroxysmal supraventricular arrhythmias (including AF) are observed in up to 38% of patients with HCM (Elliott et al., 2014; Gersh et al., 2011) and are poorly tolerated, contributing to syncopal episodes or heart failure. According to ESC guidelines, HCM patients with left atrium diameter ≥45 mm, which is considered as a risk predictor for AF and stroke, should undergo 48 hr AECG every 6-12 months to detect AF even if asymptomatic (Elliott et al., 2014) .
Ambulatory ECG monitoring is an essential part of SCD risk stratification in patients with HCM, especially in younger subjects.
Nevertheless, NSVT is characterized by high negative (95%) but low positive predictive values (Adabag et al., 2005) . Recently, published ESC guidelines recommend that the probability of sudden death at 5 years should be estimated based on the HCM Risk-SCD formula (O'Mahony et al., 2014) . This "prognostic index" integrates detected NSVT with structural abnormalities and family history of SCD, unexplained syncope and age (class IB) (Elliott et al., 2014) . 48-hr AECG monitoring to detect NSVT, defined as ≥3 PVCs at heart rate ≥120 bpm, together with clinical history and echocardiogram are considered as a first-line recommended assessment. Long NSVT episodes observed on AECG prior to an ICD implantation predicted appropriate ICD therapy during follow-up (Francia et al., 2014 ). An index of NSVT severity (heart rate × length in beats/100 > 28) was associated with over fivefold higher risk of ICD intervention. If medical therapy is used to treat ventricular arrhythmias, AECG can be repeated.
During follow-up, AECG monitoring should be repeated in the case of any symptoms suggestive of arrhythmia or routinely every 1-2 years to evaluate evidence of NSVT episodes (class IIa) or to detect asymptomatic AF episodes (class IIb) (Gersh et al., 2011) . ESC guidelines (Elliott et al., 2014) recommend longer recordings (48-hr) in all subjects and more frequent monitoring (every 6-12 months) in patients with a sinus rhythm and left atrium dimension ≥ 45 mm.
| Arrhythmogenic right ventricular dysplasia/ Cardiomyopathy
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is associated with a risk of SCD and/or progressive heart failure. Patients with ARVD/C may be asymptomatic or present with palpitations, dizziness, or syncope, potentially related to frequent ventricular ectopy or ventricular tachycardia episodes. Importantly, SCD may be the first manifestation of disease, especially in young athletes (Corrado et al., 2008) .
According to the 2010 revised Task Force criteria (Marcus et al., 2010) , ARVD/C is diagnosed based on a multidimensional scoring system. Major arrhythmic criteria for diagnosis and risk stratification include the presence of nonsustained or sustained VT of LBBB morphology with superior axis. Minor criteria include nonsustained or sustained VT of RV outflow tract morphology, LBBB with inferior or unknown axis, and presence of >500 VPBs per 24 hr. Therefore, the initial evaluation of all patients suspected for ARVD/C should include 24-hr AECG monitoring. Extension of monitoring duration to capture arrhythmias may be considered. Significant day-to-day variability in PVC burden is noted in patients with ARVD/C, but Camm et al. (2015) reported that 24-hr AECG was sufficient to document the required Task Force criterion of over 500 PVCs in nearly 90% of cases, and extension of monitoring to 96 hr increased the number of correct classification to 95.5%.
AECG has a role in patients already treated with an ICD. NSVT or PVC burden >1,000/24 hr may predict appropriate ICD discharge, the latter PVC burden associated with over threefold higher risk of ICD discharge (Bhonsale et al., 2011) . Identification of atrial arrhythmias is important as it may herald inappropriate ICD therapy, and is associated with a higher risk of heart transplantation and cardiac mortality in patients with ARVD/C (Saguner et al., 2014) .
AECG monitoring should be performed during evaluation of all first-degree relatives of patients with ARVD (Marcus et al., 2010) .
Episodes of VT with right ventricular origin pattern or more than 200
PVCs/24 hr are suggestive of familial involvement. There is no consensus on the frequency of serial re-assessment of subjects suspected for ARVD/C, but yearly assessment is reasonable. Documented electrical abnormalities, such as abnormal ECG and/or Holter, may precede structural changes during a 4-year follow-up in a cohort of ARVD/C relatives (te Riele et al., 2013) . Complex ventricular arrhythmia may be observed even when the surface ECG is normal (te Riele et al., 2014).
| Wolff-Parkinson-White syndrome
Ambulatory ECG monitoring is potentially useful for evaluation of accessory pathway conduction properties in patients with WolfParkinson-White syndrome. The risk of sudden death is related to rapid conduction across the pathway, particularly during AF, if the anterograde refractory period is short. During continuous ambulatory recordings, intermittent preexcitation or sudden loss of preexcitation with sinus rate acceleration is suggestive of "low risk," for example, those that have a shortest pre-excited RR interval during AF >250 ms (Skanes, Obeyesekere, & Klein, 2015) . AECG may also be helpful in identifying patients with WPW who have nonsustained runs of AF (Santinelli et al., 2009 ).
| Inherited primary arrhythmic diseases
Cardiac channelopathies constitute a heterogeneous group of inherited diseases such as long and short QT syndromes, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), early repolarization syndrome, and idiopathic VF, which are often caused by mutations in genes coding ion channels or regulatory proteins. They are characterized by lack of evident structural heart disease and high risk of sudden death due to ventricular tachyarrhythmias (Priori et al., 2013) . Surface ECG is a prerequisite in diagnosing these conditions and in predicting their risk of dying suddenly. Phenotype ECG expression in chanelopathies is variable; therefore, AECG monitoring may be useful in assessment of transient electrical changes suggestive of a disease. However, in patients with inherited primary arrhythmia syndromes the most important role of AECG is attributed to detection of arrhythmias and risk stratification. It should be emphasized that HRS/ EHRA/APHRS consensus on inherited primary arrhythmia syndromes (Priori et al., 2013) underlines the role of exhaustive evaluation of the origin of syncopal episodes in patients with chanelopathies. Syncope is considered a significant risk marker of SCD.
| Long QT syndrome
The long QT syndrome (LQTS) is a hereditary channelopathy characterized by QT prolongation and propensity to syncope, cardiac arrest, or sudden death in association with torsade de pointes polymorphic VT that might deteriorate to ventricular fibrillation . Recent guideline revisions suggest the diagnosis of LQTS is based on the presence of risk score ≥3 points and/or the presence of a prolonged QTc ≥480 ms interval on repeated ECGs or pathogenic mutation (Priori et al., 2015) . The risk score increases in relation to significantly prolonged QTc, torsade de pointes arrhythmias, and syncope. QT measurements are based on surface ECG; however, AECG may reveal transient prolongation of QT interval and/or inappropriate QT adaptation to heart rate. Repolarization abnormalities are frequently related to periods with abrupt changes in heart rate.
In case of progressively increasing or decreasing RR intervals, the QT interval shows a linear correlation with heart rate within physiological limits. However, in case of abrupt RR changes, the QT does not change adequately (Merri et al., 1992) . It is also documented that RR changes in the form of "short-long" cycles may precede the onset of VT in patients with LQTS (Locati et al., 1995) . AECG may be helpful in illustrating T-wave abnormalities, evaluation of R on T phenomenon, capture of T-wave alternans (an ominous finding), detection of nonsustained or sustained VT (especially torsade de pointes), in addition to identifying QT interval prolongation itself. While no doubts exist in subjects with QTc >500 ms, those with QTc <500 ms are frequently referred for exercise ECG testing and 24-hr Holter monitoring. The presence of QTc >500 ms at heart rates <100 beats per minute during exercise testing or Holter recordings may be indicative of LQTS, whereas values below 500 ms are within physiological range (Molnar et al., 1996) . Findings of inappropriate QT adaptation to heart rate or even transient QT prolongation would be clinically useful findings.
Whether AECG monitoring is required for establishing diagnosis or help in therapeutic decisions such as ICD implantation or drug titration remains unresolved. The 12-lead ECG remains the gold standard for diagnosis, however. During follow-up, AECG can be used to assess efficacy of drug therapy and its potential adverse effects such as bradycardia. Regarding noninvasive ECG risk stratification, one may consider use of AECG for detection of increased QT variability/dispersion, which are considered markers of electrical instability and therefore related to higher risk of SCD.
| Short QT syndrome
Short QT syndrome diagnosed in patients with QTc ≤340 ms is a cardiac channelopathy associated with consistently shortened QT interval and a predisposition to AF and SCD in patients with no structural heart disease (Priori et al., 2015) . Clinical manifestation of short QT syndrome may vary from totally asymptomatic to SCD as the first symptom. In the largest database of short QT syndrome patients, history of syncope was found in 24% of subjects, and the initial symptom in 14%. Palpitations were experienced by 31% of patients and were attributed to documented AF or atrial flutter in the majority of cases (Giustetto et al., 2006) . AECG in short QT syndrome is useful in identification of the cause of syncope and palpitations, particularly in detection of AF episodes, but has little role in diagnosis or guiding protective therapy.
| Brugada syndrome
Brugada syndrome is a primary inherited electrical condition characterized by abnormal repolarization pattern in the right precordial ECG leads and predisposition to life-threatening ventricular arrhythmias. The ECG diagnosis depends on a pattern of J-point elevation of 2 mm with coved ST-segment elevation and inverted T wave in V 1 -V 2 , classified as the type 1 morphology (Priori et al., 2013 (Priori et al., , 2015 , occurring spontaneously or after provocative testing. 
| Catecholaminergic polymorphic ventricular tachycardia
Catecholaminergic polymorphic ventricular tachycardia is a rare but highly lethal inherited channelopathy characterized by exercise-or emotion-induced palpitations and/or syncope in early adolescence, in subjects with no structural heart disease. SCD risk in CPVT is related to adrenergic-induced bidirectional and polymorphic ventricular tachycardia. As resting surface ECG is not helpful for the diagnosis of suspected CPVT, further electrocardiographic evaluation and provocative testing should be pursued. These tests may include AECG monitoring to assess the presence of ventricular tachyarrhythmia during daily activities and emotional stress, and above all exercise stress test to evaluate relationship of ventricular arrhythmia with increased catecholamines. Ventricular ectopy usually appears at a heart rate of 110-130 bpm and tends to aggravate in number and complexity with an increasing heart rate. Adrenergically induced atrial arrhythmias are also common.
Ambulatory ECG could be recommended as a measure of efficacy of drug treatment in patients with CPVT. Prior HRS/EHRA/APHRS statements recommended periodic AECG monitoring and exercise tests to determine the heart rate at which ventricular arrhythmia occurs and to evaluate the efficacy of arrhythmia suppression, although the presence of asymptomatic PVCs on Holter monitoring does not imply an unfavorable prognosis (Hayashi et al., 2009; Priori et al., 2013) .
| Early repolarization syndrome
Following the publication by Haïssaguerre et al. (2008) , more attention is being paid to the early repolarization pattern that had for years been considered a benign ECG finding. Several studies have documented that J-point elevation in the inferior and/or lateral leads is frequently observed in patients with idiopathic VF. Nevertheless, such an ECG pattern may also be observed in up to 31% of the general population (Macfarlane et al., 2015; Maury & Rollin, 2013; Rosso et al., 2008) . According to HRS/EHRA/APHRS consensus (Priori et al., 2013) , AECG monitoring may contribute to documentation of early repolarization pattern especially during bradycardia in survivors of VF, although the vast majority is accomplished via standard ECG.
Increase in J-point elevation amplitude preceding ventricular arrhythmias has been reported in ICD patients with electrical storm (Nam et al., 2010) . 
| Idiopathic ventricular fibrillation
| Dialysis and chronic kidney disease
The prevalence of chronic kidney disease is increasing, and it is now present in at least 15% of the adult population (Coresh et al., 2003) .
End-stage renal disease (ESRD) is characterized by extremely high mortality (20% per year), and up to 100 times higher rate of cardiovascular death, as compared to the general population (Foley, 2003) . SCD is the most common cause of death in dialysis patients (Cheung et al., 2004) .
Fluctuations of electrolytes and fluid, a chronic inflammatory state, preserved systolic function, but left ventricular hypertrophy with diastolic dysfunction, silent myocardial ischemia, and repetitive myocardial injury from dialysis-induced myocardial stunning contribute to the substrate for SCD (Bleyer et al., 2006 PVCs and VT were more common during hemodialysis than in the subsequent monitored period, and were associated with myocardial stunning. Silent myocardial ischemia was diagnosed on Holter in 22% of dialysis patients, and strongly associated with VT/VF during and after dialysis (Mohi-ud-din et al., 2005) . Interestingly, silent myocardial ischemia did not correlate with significant coronary heart disease and was thought to be due to microvascular disease and coronary spasm.
Dynamic ECG observations included a progressive increase in QRS voltage and heart rate, decrease in T-wave amplitude, and increased occurrence of arrhythmia during dialysis (Rodriguez-Fernandez et al., 2012) . Green et al., (2012) reported that microvolt TWA increased during dialysis, but did not find association between TWA and cardiovascular outcomes during 2.6 years of follow-up. Recently, an association between higher serum hemoglobin level and frequency of PVCs during dialysis was shown, which might explain the detrimental effect of high hemoglobin level on hemodialysis patients (Saygi et al., 2011) . Poulikakos et al. (2013) showed that T-wave morphology undergoes uniform rate-dependent changes during the dialysis procedure, whereas QRS-T angle changes differ from person to person, and correlated with the level of parathyroid hormone.
Recently, Buiten et al. (2014) showed that the dialysis procedure itself is associated with the development of AF. Patients receiving peritoneal dialysis showed significantly fewer episodes of AF. AF onset was more frequent on the days of the hemodialysis procedure, and during the dialysis procedure itself. Therefore, AECG monitoring during dialysis could help with the earlier diagnosis of AF in asymptomatic patients, which may prompt appropriate AF management including anticoagulant therapy.
| Neurological and muscular diseases
Perturbation of the balance of the autonomic nervous system can be studied by AECG, particularly through the analysis of HRV. Reduced HRV is generally associated with an elevated sympathetic tone or reduced parasympathetic activity. Activation of the autonomic nervous system can contribute to the genesis of a variety of arrhythmias, including both brady-and tachyarrhythmias. A strong link between epilepsy and cardiac arrhythmias has been described. Recordings during seizures report that sinus tachycardia just prior to the seizure is common, with both atrial and ventricular ectopy also observed.
However, life-threatening arrhythmias and sudden death in epileptic patients are uncommon, with a rate of approximately two in a thousand. It is possible that the same cellular mechanisms triggering cardiac arrhythmias may be responsible for cerebral epilepsy.
Myotonic dystrophy is a progressive genetic condition that primarily affects skeletal muscle but has important cardiac complications (Groh et al., 2008) . A variety of bradyarrhythmias have been observed, including sinus node dysfunction, bundle branch block, and the entire spectrum of AV blocks. Patients may also experience AF and sustained VT. Sudden death is reportedly due to asystole and ventricular fibrillation, and some patients may benefit from pacemaker or ICD. AECG may be used to detect arrhythmias to guide device and medical management, but there is little published data to guide its specific use in this clinical context.
| Sleep apnea
Sleep apnea syndrome is a common breathing disorder that affects 2%-4% of the population, with men being affected almost twice as often as women (Baranchuk et al., 2008) . The condition has welldefined associations with increased cardiovascular morbidity and mortality, arrhythmia, daytime hypersomnolence, motor vehicle accidents, and neurocognitive dysfunction, yet it is grossly underdiagnosed (Hersi, 2010) .
Recent studies have shown that cardiac arrhythmias and conduction disorders are common in patients with sleep apnea (Hersi, 2010; Todd et al., 2010) . The mechanisms of this association include autonomic imbalance, systemic and pulmonary hypertension, intermittent hypoxia, and inflammation. All these conditions facilitate structural and electrical remodeling, which is considered to be the electrical substrate for a variety of arrhythmias (Baranchuk, 2012) .
The cornerstone for the diagnosis of sleep apnea is polysomnography, during which a variety of cardiac arrhythmias (AV block, sinus pauses, NSVT, and paroxysmal AF) can be detected (Monahan et al., 2009 
| Athletes and precompetition screening
Arrhythmia monitoring of the athlete is, in some ways, distinct from utilization of monitoring in other circumstances. For the athlete, symptoms suspicious of an arrhythmia, rarely, can be a premonitory sign of SCD and may indicate an otherwise potentially serious but treatable condition or arrhythmia. On the other hand, undue restriction for suspicious but benign symptoms may be unwarranted.
A stepwise approach to evaluating the athlete should be considered. First, it is important to understand historical features of the symptoms involved and if they are related to specific competitive or physical activities. Second, it is important to rule out important cardiovascular disease that may be present concomitantly or be the initiator of the arrhythmia.
An ECG and other noninvasive tests are performed to determine the presence of any underlying structural process that could be involved and require restriction from athletics. On the ECG, there may be obvious features that point to a specific arrhythmogenic substrate. However, for many competitive athletes, the sport itself is required to initiate the symptom and potentially the arrhythmia.
Furthermore, any symptom and/or arrhythmia may not necessarily be reproducible. Thus, the AECG is one of several subsequent steps in evaluating the patient depending on the sport, the athlete, the circumstances of the symptoms, and the presence of comorbidities as well as family history.
Ambulatory ECG monitoring for the athlete is specifically useful when (1) the athlete is not already restricted due to a diagnosed cardiovascular condition; (2) there is no other way to secure a diagnosis or cause for the symptoms with any certainty; and (3) participation in athletics causes the symptoms and may facilitate the arrhythmia diagnosis. ECG monitoring can be used to secure an initial diagnosis or as a surveillance tool to ascertain that an arrhythmia is eliminated by therapy. AECG should be considered to correlate symptoms (e.g., syncope, palpitations) with arrhythmia. In addition, it may be helpful in asymptomatic patients when the initial screening ECG suggests high-density or complex ventricular ectopy to quantify the ventricular arrhythmia burden (Zipes et al., 2015) . Very frequent ventricular ectopy may suggest the presence of underlying heart disease (Biffi et al., 2002 ). In addition, some known heart conditions (e.g., congenital aortic stenosis, low-risk cardiomyopathy) and baseline ECG abnormalities (e.g., AV block, bundle branch block) may be further worked up with AECG (Pelliccia et al., 2005) .
The type of monitoring depends on symptom frequency, severity, duration, and type of circumstances surrounding the symptoms.
In addition, the type of monitoring depends on the type of athletic participation and the arrhythmia and symptom being assessed. There is no one best monitoring technique, and individualized decisions are needed.
Rhythm disturbances, by themselves, do not necessarily elicit symptoms, and some rhythm disturbances can occur with or without symptoms. On the other hand, patients may have multiple rhythm disturbances and recording an asymptomatic rhythm disturbance does not necessarily imply high risk.
| SECTION 4: HOLTER-BASED MARKERS OF AUTONOMIC NERVOUS TONE AND REPOLARIZATION
Candidate selection for ICD therapy could be improved. 
| Heart rate variability
Heart rate variability is one of the oldest Holter-based risk stratifica- <50% (Exner et al., 2007) . By contrast, the CARISMA trial investigators reported that in 312 patients evaluated at 6 weeks after an acute myocardial infarction, SDNN, very low frequency (VLF), high frequency (HF), and fractal scaling component independently predicted all-cause mortality and arrhythmic events documented by an ILR . In heart failure patients, decreased HRV has been documented as a potent marker of heart failure progression and identified patients in need of heart transplantation or with elevated risk for death due to pump failure. The GISSI Holter substudy in a contemporary population of heart failure patients showed that SDNN, VLF, LF, and detrended fluctuation analysis were independent risk predictors for cardiovascular death, while VLF and LF were associated with sudden death or appropriate ICD discharge (La Rovere et al., 2012) .
Despite data linking decreased HRV with increased mortality, randomized trials in patients stratified for ICD implantation based on this parameter failed to demonstrate the usefulness of HRV in predicting benefit from ICD therapy (Hohnloser et al., 2004; Steinbeck et al., 2009 ). Patients with impaired HRV at enrollment were more likely to die from heart failure progression than from arrhythmic causes. In fact, HRV algorithms are currently implemented in cardiac resynchronization therapy (CRT) devices to identify heart failure exacerbation (Landolina et al., 2008) . Additionally, the DEFINITE trial showed that preserved HRV, defined as SDNN >100 ms, identified patients without sudden death or ICD shocks during a 3-year follow-up (Rashba et al., 2006) . Most commercial Holter systems are equipped with software for automated analysis of time-and frequency-domain HRV measures.
| Heart rate turbulence
Heart rate turbulence analyzes the baroreceptor-mediated response of the sinus node to premature ventricular beats composed of an early acceleration and subsequent deceleration and is an indicator of baroreceptor sensitivity (Schmidt et al., 1999; Bauer et al., 2008 (Bauer et al., 2008; Cygankiewicz, 2013) .
The initial evidence of the usefulness of abnormal HRT to stratify risk for all-cause mortality (Schmidt et al., 1999) in postmyocardial infarction was confirmed in patients receiving guidelinedirected medical therapy and early revascularization by PCI (Barthel et al., 2003; Exner et al., 2007; Makikallio et al., 2005) . The FINGER (FINland and GERmany Postinfarction) study documented that only abnormal turbulence slope (TS) and NSVT were significantly associated with an increased risk of SCD; patients with abnormal slope had almost threefold higher risk than those with normal slope (Makikallio et al., 2005) . The REFINE (The Risk Estimation Following Infarction Noninvasive Evaluation) trial reported that abnormal HRT analyzed at 10-14 weeks after myocardial infarction predicted the primary endpoint of cardiac death or resuscitated cardiac arrest in post-MI patients with LVEF <50% (Exner et al., 2007) . Abnormal TS evaluated at 6 weeks after MI identified patients with LVEF <40% who were at risk for arrhythmic events such as ventricular fibrillation or symptomatic VT during the 24-month follow-up ). Combined analysis from REFINE and CARISMA studies reported that in acute postmyocardial infarction patients, absence of an increase in TS values was associated with sevenfold to 10-fold higher risk of life-threatening arrhythmias during a 2-year follow-up (Huikuri et al., 2010) . In patients with heart failure, abnormal HRT is associated with an increased risk of all-cause mortality and heart failure progression. Moreover, both the MUSIC and GISSI-HF trials, which enrolled ambulatory patients with mild-to-moderate heart failure, documented that abnormal TS predicts not only total mortality but also SCD and/or appropriate ICD discharge La Rovere et al., 2012) . Abnormal HRT seems to be particularly useful in identifying high-risk patients among those with LVEF >30% (Bauer et al., 2008; Cygankiewicz et al., 2009; La Rovere et al., 2012) and is frequently evaluated in risk scores that combine assessment of arrhythmogenic substrate (low LVEF), repolarization instability (e.g., TWA), and abnormal autonomic nervous system tone (HRV). The REFINE study showed that patients with both abnormal HRT and TWA had a fourfold higher risk of arrhythmic events, while the MUSIC study documented that a combination of abnormal TS, decreased SDNN, and increased repolarization dynamicity (QT/RR) was associated with the highest risk of sudden death in patients with heart failure and LVEF >35%. The value of combined risk stratification including HRT was also observed in GISSI-HF trial (Cygankiewicz et al., 2009; Exner et al., 2007; La Rovere et al., 2012 ). QT dynamics may have a greater incidence of malignant arrhythmias (Jackman et al., 1988; Moss & Schwarz, 1982; Roden, 1991) .
| QT variability and dynamics
The QTV Index measures repolarization lability by calculating the ratio of repolarization variability to HRV. Specifically, it assesses beatto-beat variability of the duration of the QT interval and U wave with concomitant evaluation of the circadian rate-adjusted QTV and RR interval variability (Berger et al., 1997) . Increased QTV index is associated with both all-cause mortality and cardiovascular mortality in patients with acute myocardial infarction or heart failure and in resuscitated cardiac arrest (Dobson et al., 2013) .
Recent ESC guidelines on ventricular arrhythmias and SCD do not recommend noninvasive risk stratification in the early postinfarction phase (Priori et al., 2015) given the limited sensitivity and positive predictive values of various Holter-based parameters to improve SCD risk stratification, including quantitative analysis of T-wave alternans (Gold et al., 2008; Kentta et al., 2014; Verrier et al., 2011; Verrier et al., 2013; Chow et al., 2008; Zipes et al., 2006; Nieminen et al., 2014; UchimuraMakita et al., 2014) . However, efforts to improve this continue, since sudden death occurs largely in subjects in whom left ventricular ejection fraction has proven insufficient for risk stratification. A recurring theme is that the use of the multiparameter approach incorporating indicators of autonomic tone and repolarization abnormality holds the greatest promise. The absence of randomized clinical trials to assess the capacity of these parameters to guide therapeutic interventions to prevent SCD is a major deficiency.
| SECTION 5: CLINICAL INDICATIONS-PRETREATMENT ARRHYTHMIA ASSESSMENT AND DOCUMENTATION OF THE EFFICACY AND SAFETY OF PHARMACOLOGICAL AND NONPHARMACOLOGICAL THERAPY IN SPECIFIC CLINICAL CONTEXTS
| Ventricular arrhythmias
| PVC monitoring
AECG facilitates detection, quantification, and morphology assessment for the evaluation of the overall PVC burden as a potential cause of "tachycardiomyopathy" (Baman et al., 2010) and correlation between symptoms and ECG findings, for example, intense physical activity or emotional stress (Cantillon, 2013; Zipes et al., 2006) . AECG may be analyzed for relationship between ventricular arrhythmia and preceding heart rate and repolarization changes (e.g., transient QT prolongation) or ischemia (Diem et al., 2002; Lewis et al., 1983) . These factors are important for directing (and assessing efficacy and safety of therapy) (Aliot et al., 2009; Cantillon, 2013; Katritsis et al., 2013; Pedersen et al., 2014) . Three-channel AECGs are suitable for detection and quantification of ventricular arrhythmia burden. However, 12-channel recorders more reliably diagnose PVC origin (and reveal aberrant supraventricular conduction as a cause for wide complexes), useful for decisions regarding catheter ablation.
| Suppression of ventricular arrhythmia by pharmacotherapy
Treatment of ventricular arrhythmias is sometimes utilized for relief of symptoms and/or suppression of frequent PVCs that cause left ventricular dysfunction (Pedersen et al., 2014) . 
| Atrial fibrillation
| ECG recording modalities
As symptoms during AF are largely nonspecific (or absent), extended AECG recording is helpful to clarify the need for additional treatment (such as pacemaker), to help reassure the patient, and to predict longterm prognosis (Kennedy, 2015) . In addition, other arrhythmic causes of symptoms, such as atrial flutter, atrial tachycardia, atrial ectopy, and others can usually be differentiated from AF, especially with multilead recordings (Mittal et al., 2011) . Notably, AF may be triggered by other arrhythmias, for example, AVRT or AVNRT, especially in younger patients, and it is important to document this before selecting appropriate treatment (Calkins et al., 2012; Sauer et al., 2006) . Some patients exhibit very-high-density atrial ectopy that can serve as AF triggers as well, and 24-hr recordings that contain >1,000 atrial premature beats may be candidates for ablation of these "focal triggers" (Calkins et al., 2012) .
The definition of AF has been set as a minimum of 30 s (Calkins et al., 2012) , but this is not based on any data analysis of AF duration and patient outcome. In clinical practice, this severe definition may
give way to one that also takes account of AF frequency, duration, and symptom status. Duration and frequency of events vary greatly among patients with AF. Therefore, the choice of AECG to capture AF episodes will be determined by duration and continuity of recording (Mittal et al., 2011) . AECG can quantify atrial and repetitive ectopy, shortest and longest duration of AF, burden of AF, the heart rate during AF, and pattern of initiation and termination of AF. Short-duration 24-to 72-hr Holter recordings are best suited for patients with very frequent paroxysms of AF or persistent AF. For less frequent episodes, patient-activated event and loop recorders can be used for several weeks at a time. These devices are particularly useful to capture ECG recordings during symptomatic events and clarify the arrhythmic basis for unexplained or ambiguous symptoms, especially if infrequent.
Autotriggered devices have higher diagnostic yield than standard 24-hr Holter monitors and 30-day loop recorders (Reiffel et al., 2005) .
Although these monitors can detect the onset of an arrhythmia such as AF, their algorithms are not designed to include the offset of the arrhythmia. Thus, information about the burden of AF cannot be consistently ascertained. Patch monitors and MCT are the most complete outpatient ECG recording and increase the likelihood for detecting AF, and can provide accurate representation of AF burden for the duration of recording (Barrett et al., 2014; Rosenberg et al., 2013; Rothman et al., 2007; Turakhia et al., 2013; Schreiber et al., 2014) .
Reliance on symptoms alone (by patient or physician) may be misleading-both over and underestimating the presence of AF (Charitos et al., 2014) . This has important implications for assessing treatment effects including interventional ablation (Calkins et al., 2012; Joshi et al., 2009; Steinberg et al., 2014) . Indeed, catheter ablation may increase the proportion of AF events that are asymptomatic, probably by alteration of cardiac neural element (Hindricks et al., 2005) . As most patients do not have an implanted device, extended AECG facilitates accurate AF quantification and associated ventricular rates.
| Cryptogenic stroke
Twenty-five percent of ischemic strokes remain unexplained after an initial thorough evaluation including 12-lead ECG and in-hospital telemetry monitoring and full neurological workup, that is, "cryptogenic stroke" (Wolf et al., 1987) . AF and associated thrombus formation is the most common cardioembolic source of ischemic stroke (Liao et al., 2007) . Because the formal diagnosis of AF leads to an effective medical intervention with chronic oral anticoagulation (rather than aspirin), it is critical to identify AF in patients with cryptogenic stroke (Hart & Halperin, 2001 ). Postdischarge AECG recording after cryptogenic stroke has particular utility (Marini et al., 2005) although AF detection is sensitive to the patient selection process, the definition of AF, and the duration of monitoring. The minimal duration of AECG monitoring is uncertain, and 30-day recordings have identified as high as a 20% prevalence of AF (Kishore et al., 2014) . A recent randomized clinical trial involving 572 patients compared 30-day AECG monitoring to 24-to 48-hr Holter recording and found the respective yield to be 16.1% versus 3.2% for AF >30 s and 9.9% versus 2.5% for AF >2.5 min, with a resultant increase in prescription of anticoagulant therapy (Gladstone et al., 2014) . If detection is thought to require more prolonged monitoring, AECG may be limited by noncompliance and an ILR may be more effective with a sixfold increased detection rate of AF >30 s at 6 months of follow-up in a trial that used a control group with little AECG monitoring (Sanna et al., 2014) . The optimal AF detection strategy and monitoring duration are undefined and definitive recommendations will depend on cost-efficacy, patient acceptance and compliance, clarification of AF definitions, and demonstration of enhanced stroke reduction by a specific approach.
| Acute treatment assessment-"pill-in-thepocket" approach
An alternative to emergency department treatment for patients with infrequent but disabling AF is the "pill-in-the-pocket" strategy (Alboni et al., 2004) . AECG monitoring can provide important efficacy and safety data in the outpatient setting, that is, confirmation of AF occurrence and absence of spontaneous termination prior to using the antiarrhythmic drug, or after therapy has been self-administered, confirmation of success or failure that may require alternative management strategies. Possible complications (e.g., posttermination pauses) can also be captured by AECG.
| Posttreatment assessment-pharmacologic therapy
Rate control correlate rate with residual symptoms should be individualized and may require extended ECG recording, for example, in patients with heart failure and/or ventricular dysfunction.
Rhythm control
The goal of a rhythm control strategy is to suppress or reduce the prevalence of AF associated with symptoms. Therefore, it may be reasonable to perform AECG to confirm the presence or absence of AF, particularly if residual symptoms are ambiguous or resting ECGs have been inconclusive.
Safety of pharmacotherapy
Outpatient monitoring with AECG may be used when starting antiarrhythmic drugs that do not require hospitalization for initiation. Class 
| Drug trials and safety (QT and arrhythmia evaluation)
Drug-induced QT prolongation has been recognized as a side effect of many commonly used medications. A prolonged QT interval predisposes to the development of ventricular tachyarrhythmias such as torsade de pointes and ventricular fibrillation, which could cause syncope, cardiac arrest, or SCD (Haverkamp et al., 2000; Moss, 1999; Zareba et al., 1995) . Medications representing numerous classes of drugs have been shown to cause QT prolongation, usually via the mechanism of blocking IKr potassium current. The vast majority of older patients take several drugs, so an interaction of two or more drugs might increase the risk of QT prolongation and proarrhythmia.
A standard 12-lead ECG is used in daily clinical practice to evaluate QT prolongation, whereas telemetry monitoring, event recorders, or
Holter monitoring are utilized to assess arrhythmias. snapshots of the definitive 12-lead ECGs provide an insight into continuous assessment of arrhythmias (Sarapa et al., 2004) .
Recent data from five thorough QT studies (Ferber et al., 2015) utilized access to continuous Holter recordings to further decrease variability in QT measurements by analyzing a larger number of beats.
This approach demonstrated that Holter monitoring in early phase I and II studies could provide effective assessment of QT prolongation with smaller sample sizes without conducting separate and costly thorough QT studies . This approach could be further enhanced by drug exposure to QT response analysis empowered by continuous Holter monitoring .
| Ambulatory ECG monitoring in patients with cardiac implantable devices
AECG monitoring plays an essential role in establishing indications for pacemaker implantation. In some cases, it is useful for evaluation of already implanted patients although current era implantable electronic devices (pacers, ICDs, and CRTs) have sophisticated remote monitoring capabilities that are able to evaluate electrical properties of the device itself and also arrhythmias (Andrikopoulos et al., 2010; Barold, 1998; Dubner et al., 2012; Mittal et al., 2014; Mittal & Steinberg, 2012; Ritter, 2013; Varma & Auricchio, 2013; Varma & Ricci, 2013) .
Nevertheless, AECG may be helpful for arrhythmia analyses needed for correct device programming to deliver appropriate therapy, to avoid inappropriate intervention, or to detect device malfunction. 
| Indications for implantation and evaluation prior to implantation
| Evaluation during follow-up
Advances in technology and clinical experience acquired over the past decades indicate that routine ECG monitoring after implantation is not necessary. Myopotential inhibition, cross talk, and pacemaker-mediated tachycardia, which constitute the major abnormalities in Holter recordings performed in pacemaker patients, are infrequently encountered, and may be detected and notified by remote monitoring, if and when they occur. However, AECG may be useful to correlate symptoms suggestive of arrhythmias or device malfunctioning. For example, AECG may also be helpful in patients with devices to assess upper rate pacemaker behavior with exercise, that is Wenckebach or 2:1 AV block, and the device could be reprogrammed accordingly.
AECG monitoring can be performed in patients with symptoms suggestive of device malfunctioning such as intermittent loss of capture or sensing abnormalities that may lead to clinically significant pauses or tachyarrhythmias in patients in whom routine interrogation does not reveal the reason for corresponding clinical symptoms.
Notably, other causes of syncopal episodes are frequently observed in patients with pacemakers. In one report, only 4.9% of patients were found to have pacemaker dysfunction as a cause of syncope (DeCicco et al., 2014; Ofman et al., 2013) .
Evaluation of atrial and ventricular arrhythmia by device software and retrieved diagnostics may not always be complete (Kumor et al., 2010) . Atrial arrhythmias may be characterized and quantified by AECG to guide proper treatment. Patients in whom arrhythmia counters show frequent PVCs may be treated with ablation procedure, which may be directed by a 12-lead AECG to evaluate exact morphology of PVCs and/or VT episodes. Furthermore, slow VT episodes below detection threshold can only be assessed externally.
Even though the results of randomized clinical trials have provided the optimal programming of primary prevention ICD devices (Moss et al., 2012; Wilkoff et al., 2016) , AECG monitoring and exercise testing may be useful in individual optimization of ICD settings in some difficult cases.
Benefit from CRT depends mostly on the effectiveness of biventricular pacing and programming should assure the maximum (>98%) of biventricular pacing (Wilkoff et al., 2016) . Therefore, such an evaluation should be recommended especially in nonresponders or in those who initially responded to CRT and then deteriorated during follow-up.
As the number and chronicity of implantable devices increase, the number of patients undergoing explants for device problems and/or infections is increasing. The need for reimplantation has to be established even before explantation, and therefore, monitoring of symptoms and ECG with a device programmed at a pacing rate below the patient's intrinsic rate is recommended. Both European and American guidelines underline that after device removal, careful reassessment of indications for reimplantation should be performed on an individual basis to determine risk-benefit ratios (Habib et al., 2009; Wilkoff et al., 2009 ).
| SECTION 6: HOSPITAL-BASED CARDIAC TELEMETRY AND CONTINUOUS RHYTHM MONITORING
Hospital-based cardiac telemetry and continuous rhythm monitoring are important hospital resources for the detection and treatment of cardiac arrhythmias. Though utilized worldwide, there is a surprisingly dearth of evidence for their application regarding selection of at-risk candidates and alarm management, but recent recognition of harms associated with alarm fatigue.
| Technical aspects
Hardwired continuous cardiac rhythm monitoring systems involve connections to monitoring equipment by cable using either digital or analog signals for data transfer. These are utilized within intensive care units with immobilized critically ill patients. Cardiac telemetry refers to remote monitoring with wireless data transfers using a radiofrequency signal, typically applied on medical or surgical hospital wards to allow patient ambulation. Hospital-based monitoring most commonly involve three, five, or six leads, and less commonly 12 leads. Fewer leads simplify connections and nursing workflow, and add less bulk, but attenuate ability for myocardial ischemia detection with continuous ST-segment monitoring (Drew & Krucoff, 1999) .
Competency is required in both the afferent and efferent communication limbs of continuous cardiac rhythm monitoring. Attention to skin preparation, electrode placement, and equipment connections represents a critical first step. Incorrect electrode placement was found in 26% in one study, but improved with educational interventions (Pettersen et al., 2014) with immediate direct impact on signal quality of monitoring (reducing noise artifact). Arrhythmia recognition requires both dutiful attention to the clinical alarms and also sufficient knowledge to delineate true arrhythmia events from noise artifact.
False positives may lead to inappropriate medical interventions (Knight et al., 1999 
| Alarm fatigue
Nominal alarm default settings are designed to be highly sensitive so as to not miss a clinically important event, but can also demonstrate poor specificity. Alarm fatigue is defined as desensitization from a high alarm volume with a low yield of clinically relevant findings and has potentially serious adverse clinical consequences (Sendelbach & Funk, 2013 (Atzema et al., 2006; Chambrin et al., 1999; Lawless, 1994; Siebig et al., 2010; Tsien & Fackler, 1997) . Telemetry findings can be low yield and altered management in only 7% of cases in one study evaluating over 2,000 non-ICU patients (Estrada et al., 1995 Addressing alarm fatigue may improve clinical outcomes. Simply improving skin preparation with fine sandpaper and daily electrode replacement reduced alarms by 46% (Clochesy et al., 1991; Cvach et al., 2012; Pettersen et al., 2014) . Empiric adjustments of the default heart rate settings (upper limit 130-135 bpm and lower limit of 40-45 bpm) safely reduced clinical alarms in a general medical surgical ward (Burgess, 2009 ).
| Standardized cardiac telemetry
Patient selection may be important. Monitoring low-risk patients who are unlikely to experience cardiac arrhythmias may yield a disproportionate ratio of false alarms including noise artifact and ECG lead failures. For example, arrhythmia yield was only 1.5% in one study of "low-risk" hospitalized patients admitted with chest pain and normal or nonspecific ECG findings (Hollander et al., 1997) . The AHA prac- 
| Centralized monitoring
Dedicating "watchers" for continuous rhythm monitoring has been previously associated with an improvement in the fidelity of true rhythm recognition events in prior studies, including reduction in sustained ventricular tachycardia events-presumably owing to earlier interventions for nonsustained events (Cantillon et al., 2016; Funk et al., 1997; Stukshis et al., 1997) . However, the feasibility of continuous human monitoring of multiple screens is questionable and costly, pulling nurses away from direct patient care and education (Drew et al., 2004) . Automated electronic alarms hold promise; however, heavy reliance on these has generated alarm fatigue. 
| SECTION 7: TELEMETERED CARDIAC REHABILITATION
Telerehabilitation is a technique by which skilled rehabilitation services can be delivered in the home and community-based setting, potentially increasing accessibility and adherence to rehabilitation processes.
Home-based cardiac rehabilitation programs were introduced in the early 1980s using ECG transtelephonic monitoring and were found to be efficacious and safe (Fletcher et al., 1984) . Transtelephonic exercise monitoring was as efficacious as hospital-based standard rehabilitation programs in improving functional capacity (Shaw et al., 1998) and provided clinically significant improvements in risk factors and exercise capacity at the end of 4 weeks following cardiac surgery (Zutz et al., 2007) . The virtual cardiac rehabilitation program included on-line intake forms, scheduled one-to-one chat sessions, and weekly education sessions. Thus, integrated telemedicine services by providing surveillance, education, psychological support, and interactive motivational tools have the potential to monitor cardiovascular risk factors and to significantly affect morbidity and mortality on a large scale (Piotrowicz & Piotrowicz, 2013) .
Home-based telemonitored cardiac rehabilitation is also feasible and safe in patients suffering from heart failure (Kouidi et al., 2006; Piotrowicz et al., 2010; Smart et al., 2005) . Following an 8-week training program, significant improvements were observed in NYHA class, peak oxygen consumption, 6-minute walking test distance, and quality of life scores. In addition, no worrying signs or symptoms were observed during training, nor it was necessary to stop rehabilitation urgently in any patient. However, the evidence for the value of telemedicine in managing chronic heart failure is not yet definitive (Wootton, 2012) . While a Cochrane Collaboration review and metaanalysis reported that telemedicine (structured telephone support or telemonitoring) significantly reduced heart failure-related hospitalizations (Inglis et al., 2011) , these results were not confirmed by two subsequent large randomized controlled trials (Chaudhry et al., 2010; Koehler et al., 2011) .
| SECTION 8: DATA MANAGEMENT, REIMBURSEMENT, AND LEGAL CONSIDERATIONS
| Integration with the electronic health record
There is increasing interest in integrating reports emanating from AECG monitoring systems with the patient's electronic health record (EHR). This requires an interface (preferentially a bidirectional interface) based upon the Health Level Seven (HL7) information exchange standard, which provides the framework for the exchange, integration, sharing, and retrieval of electronic health information (Figure 4 ).
Most commonly, a PDF is created to "display" the data acquired by an AECG system for an event or over a prespecified monitoring period (e.g., event, daily, weekly, and/or end of monitoring summary report).
The PDF file can be manually attached to a patient's EHR; alternatively, an automatic interface can directly integrate the PDF file into the EHR. In this scenario, the clinician receives a message within the EHR that a test result is available for review. The PDF can then be accessed either directly from within the message or through a URL link incorporated within the message.
| Reimbursement
In the USA, individual insurance carriers define the frequency of monitoring as well as the indications for monitoring. The Centers 
| Legal considerations
Currently available autotriggered loop recorders and ambulatory cardiovascular telemetry systems have the capability of wireless data transfer to an independent diagnostic testing facility via a cellular network. As a result, practices must ensure that they have a mechanism in place to handle incoming data on a 24/7/365 basis to ensure that potentially life-threatening arrhythmias are rapidly identified and treated. As patients are monitored for up to a month at a time, a significant amount of ECG data accumulates for physician review. Vendors have established nominal physician notification criteria; these often overestimate the clinical significance of captured arrhythmias and generate needless calls to physicians and/or Emergency Medical Services. Therefore, it is highly recommended that practices develop specific notification criteria to prevent being inundated by after hour calls related to nonurgent arrhythmic detections. Table 6 outlines an example of notification criteria that have been developed to minimize unnecessary calls to patients and after hour calls to physicians yet ensure patient safety in the event a lifethreatening arrhythmia is detected. It is hoped that these types of robust criteria can minimize the legal liability to a practice by minimizing the likelihood that they will fail to respond to clinically important AECG information.
Heterogeneity among European countries makes it difficult to generalize legal ramifications. In some, there are already available legal solutions but in most these are under development. The Green Paper on mobile health (mHealth) announced in the eHealth Action Plan 2012-2020 may produce a common platform (European Commission, 2014) . Its objective is to launch a broad stakeholder consultation on existing barriers and issues related to mHealth deployment and help identify the right way forward to unlock mHealth potential to maintain and improve patients' health and well-being and encourage their empowerment.
| SECTION 9: EMERGING TECHNOLOGIES
| Use of smartphone technology for AECG recording
Smartphone-based AECG is a potentially disruptive technology, blurring the traditional models of prescribed device and physician interpretation, and also definitions of patient versus consumer. Already, over 50 million Americans wear a connected device to track activity and that number is expected to grow to over 160 million with the recent introduction of the "smart" watches. Almost all activity sensors include heart rate and some chest-worn body sensors include ECG. The ability to record an ECG is increasingly seen as an important requirement in the biometric monitoring of elite athletes.
For heart rhythm monitoring, some technologies partner sensors into smartphone casing to record an ECG tracing which can be interpreted by the patient or transmitted to a physician. These therefore function as patient-activated intermittent nonlooping AECGs. For AF, these have been applied for screening and for monitoring response to therapy (at time of writing, one such device has received FDA clearance for this purpose). They may be particularly useful in pediatric populations. For elite athletic screening, such single-lead AECG recordings have been shown to be equivalent to 12-lead ECG screening for detection of rate and rhythm disturbances and for assessment of conduction intervals (Haberman et al. 2015; Lowres et al., 2014; Nguyen et al., 2015; Tarakji et al., 2015) . Newer implantable cardiac implantable electronic devices (e.g., ICDs) may relay their data directly via smartphone apps. This may facilitate remote monitoring of these devices that has been recommended as standard of follow-up care. This removes the current transceiver that has been a traditional impediment to remote monitoring implementation due to phone incompatibility, lack of portability, and cost. 
| Wearable cardioverter defibrillator
The wearable cardioverter defibrillator (WCD) is playing a more prominent role in the management of patients as a bridge or temporary substitute for ICDs. Current WCDs have embedded remote monitoring capability. This online remote patient management system allows clinicians to monitor data downloaded from a patient's WCD.
The patient downloads through the base station/battery charger. The device connects to it with Bluetooth and is then encrypted and sent wirelessly via cellular networks to the secure network website where it is archived for review. The patient receives a confirmation on the screen once a download is completed. Information on the network can be accessed anytime and the dashboard page allows clinicians to triage multiple patients based on customized settings. Examples of events that can trigger alerts include the following: shock treatments, patient-initiated ECG recordings, and detected arrhythmia where no treatment was given (e.g., short runs of VT). Importantly, bradycardic events and AF can also be discovered. Clinicians can elect to be notified when a patient triggers an alert. ECGs may be captured by manual recording or automatically delivered from an event (i.e., SVT, NSVT, asystole). A 2-channel ECG can be viewed online. Some of these recorded events may support ICD implantation. Apart from continuous arrhythmia monitoring, the remote monitoring system can chart compliance (wear time on a daily basis), patient activity, and orthopnea, potentially important for heart failure management (Kutyifa et al., 2015) .
F I G U R E 4 Electronic Health Record (EHR) integration workflow. The EHR contains information about the patient, which is captured at registration. In this example, the practice is using a third-party provider for ambulatory electrocardiographic monitoring. The EHRPipe is an interface of interrogation engine that serves as a bidirectional bridge between this provider and the EHR system (courtesy of ScottCare, Inc.)
| SECTION 10: FUTURE NEEDS
The rapid pace of evolution of AECG devices, along with evolving changes in indications, duration, and intensity of monitoring, have resulted in several key knowledge gaps and unmet needs.
| Education and regulatory oversight of consumer-grade wearables
Mobile smartphone devices have enabled a new class of consumergrade wearable monitoring devices, colloquially referred to as "wearables." With few exceptions, almost all wearable devices have entered the consumer or retail space, generally with no medical regulatory oversight or approval. Although most of these devices are designed to measure heart or pulse rate rather than rhythm, the sensitivity and specificity for heart rate, let alone, arrhythmia detection, are poorly defined, and there is limited information on the agreement of these devices with medical-grade lead-based ECG monitors (Parak & Korhonen, 2014 
| Decision support for data interpretation and precision medicine
As the wear time of AECG devices increases due to technological enhancements, the yield of detected arrhythmias is expected to increase proportionally. For example, patients wearing a patch-based ECG monitor for up to 14 days, the yield of AF beyond 48 hr (the traditional Holter monitor duration) is substantial (Barrett et al., 2014; Turakhia et al., 2015) . Finally, devices vary in their definitions of arrhythmias, including AF, and sustained and NSVT. As newer devices detect shorter and shorter arrhythmia episodes over longer monitoring periods, the clinical significance of these episodes may be uncertain and clinicians may struggle with decision making for treatments such as anticoagulation. Improved decision models are needed to help guide clinicians. Large datasets derived from population of patients with noninvasive or implantable monitors, linked to clinical events from EHR, may be useful to provide more robust, individually tailored estimates of long-term and short-term risk of events and potential benefits and harms of therapies (Inglis et al., 2011) . Novel analytical techniques, such as machine learning, may help to identify patterns of risk not readily apparent simply based on arrhythmia burden or standard multivariate regression techniques, particularly if framed using a Bayesian rather than frequentist statistical methodology. Similar techniques may also be useful to help clinicians more accurately risk stratify and triage various conditions based on inpatient telemetry, such as syncope.
| Data management and integration in EMR or adjacent EMR platforms
Most of the current monitoring solutions provide the data and interpretation to clinicians in the form of a report rather than structured or raw data. These reports, while clinically useful, are generally freestanding digital documents that are scanned or imported into the EMR as image or media. These data generally cannot be overlaid with other structured EMR data, such as vital signs, laboratory data, or medications. As a result, the synthesis of the AECG data with other EMR data must be actively performed by the clinical service or practice, leaving great potential for human error. As a result, methods to import 
| SECTION 11: CONCLUSIONS AND RECOMMENDATIONS
Accurate and timely diagnosis of arrhythmias is crucial to direct therapies that can make an important impact on patient care and healthcare utilization. The rhythm information derived from the large spectrum of AECG recording systems can often lead to appropriate and patient-specific medical and interventional management. 
Class of recommendation
Level of evidence
A. Selection of AECG T A B L E 6 Physician notification criteria for ambulatory cardiovascular telemetry
Emergency criteria:
1. The vendor will always call the patient for ascertainment of symptoms and to obtain a follow-up recording (regardless of time of day and whether the recording with automatically or patient triggered) 2. This is the only situation that the vendor will place a call to the patient 3. If the patient presents with an ECG meeting emergency notification criteria and the physician cannot be reached, the vendor will activate emergency medical services (EMS) 4. ECG recordings that meet criteria for emergency notification may include the following: a. Sustained, regular, wide complex tachycardia at ≥160 bpm b. Prolonged asystole
24-hr notification criteria:
1. The vendor will notify the physician's office, or the on-call physician, when a patient transmits a recording that meets 24-hr notification criteria 2. ECG recordings that meet criteria for 24-hr notification include the following:
•. Sustained, regular, wide complex tachycardia at <160 bpm •. Sustained, regular, supraventricular tachycardia ≥150 bpm if reported by the patient as being associated with symptoms (manually triggered), otherwise office-hour notification •. Pause ≥4-s if reported by the patient as being associated with symptoms (manually triggered), otherwise office-hour notification •. Type II second-degree or third-degree atrioventricular (AV) block, whether or not associated with symptoms •. All reported syncopal episodes •. All observed pacemaker malfunction episodes •. All reported or observed ICD discharges •. Sustained bradycardia (heart rate ≤30 bpm) if reported by the patient as being associated with symptoms (manually triggered), otherwise office-hour notification
Office hour (9 a.m.-5 p.m. 7 days a week) notification criteria:
1. The vendor will notify the physician's office the same day if recorded between the hours of 9 a.m. and 5 p.m., or the following day if obtained after 5 pm 2. ECG recordings that meet criteria for office hour notification include the following:
•. Atrial fibrillation and/or flutter i. New onset (as documented by the vendor) with a duration ≥30 s ii. Ventricular response ≥150 bpm for ≥60 s •. Wide complex tachycardia ≥120 bpm lasting between 3 beats and 30 s and not meeting EMS or 24-hr notification criteria •. Type I second-degree AV block 2 The consensus recommendations in this document use the commonly used class I, IIa, IIb, and III classifications and the corresponding language according to the most recent statement of the ACC. Class I is a strong recommendation, denoting benefit greatly exceeding risk. Class IIa is a somewhat weaker recommendation, denoting benefit probably exceeding risk, and class IIb denotes benefit equivalent or possibly exceeding risk. Class III is a recommendation against a specific treatment, because either there is no net benefit (benefit is equal to the risk) or there is net harm (risk outweighs the benefit). Level A denotes the highest level of evidence, usually from multiple clinical trials with or without registries. Level B evidence is of a moderate level, either from randomized trials (B-R) or well-executed nonrandomized trials (B-NR). Level C evidence is from weaker studies with significant limitations (e.g., randomized or nonrandomized observations or registry; studies with limitations of design or execution; meta-analyses of such studies; physiological or mechanistic studies in human subjects), and level E is simply a consensus of experts opinion based on clinical experience when evidence is insufficient, vague, or conflicting.
Class of recommendation
